ArticleTherapeutic advances in gastroenterology2023

Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis.

Youwen Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.